Boro Dropulic is a rarity in the biotech world. The founder and CEO of the Baltimore-based gene therapy company, Lentigen, is a scientist at heart — but his credentials also include an MBA from Johns Hopkins University.

“It’s important to really, truly integrate the business vision with the science,” said Dropulic, who moved to Maryland from Australia in 1988 for a job at the National Institutes of Health.

Recommended Stories

D.C.’s $50M venture fund on track to meet target

Local technology firms angle for Capital Connection 2007 venture capital opportunities

District mayoral candidates debate future of city’s technology industry